Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Fang-Shu Ou"'
Autor:
Manish Kohli, Hugues Sicotte, Eric D. Wieben, Ping Yin, Zhenqing Ye, Michael Gormley, Sisi Qin, Henry C. Pitot, Haojie Huang, Fang Xie, David W. Hillman, Vipul Bhargava, Rachel Carlson, Brian A. Costello, Winston Tan, Thai H. Ho, Patrick W. Eiken, Rafael E. Jimenez, Krishna R. Kalari, Bruce W. Eckloff, Yingming Li, Brendan P. McMenomy, Marissa S. Ellingson, Steven N. Hart, Scott M. Dehm, Liguo Wang, Fernando Quevedo, R. Qin, P. Barman, Fang-Shu Ou, Thomas D. Atwell, Alan H. Bryce, Jin Jen, Peter T. Vedell, Richard M. Weinshilboum
Publikováno v:
Annals of Oncology. 29:352-360
Background Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known. Patients and methods In a prospec
Autor:
Naim U. Rashid, Stefanie Denning, Federico Innocenti, Monica M. Bertagnolli, H. J. Lenz, Xueping Qu, M. Wancen, Charles D. Blanke, Alan P. Venook, O. Kabbarah, Fang-Shu Ou
Publikováno v:
Annals of Oncology. 30:v198-v199
Background CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that found no difference in overall survival (OS) in first-line mCRC Patients (pts) treated with bevacizumab (Bev) or cetuximab (Cet) combined with the same chemotherapy. By appl
Autor:
A. Grothey, O. Crysler, A. Elsing, Briant Fruth, Andrew B. Nixon, Patrick McKay Boland, Niharika B. Mettu, H. J. Lenz, R. Breakstone, Christina Wu, Marwan Fakih, Thorvardur R. Halfdanarson, Emily Bolch, Erin Twohy, B. Schweitzer, Fang-Shu Ou, Herbert Hurwitz, Donna Niedzwiecki, T. S. Bekaii-Saab
Publikováno v:
Annals of Oncology. 30:v203
Background The benefit of immune checkpoint blockade in mCRC is currently limited to mismatch repair (MMR) deficient tumours. Increasing evidence suggests that the vascular endothelial growth factor (VEGF) pathway plays a role in cancer immune evasio
Autor:
Daniel R. Almquist, Daniel H. Ahn, E. Wolfe, Kabir Mody, Mitesh J. Borad, Fang-Shu Ou, Kristen K. Ciombor, Reham Abdel-Wahab, T. S. Bekaii-Saab, Milind Javle, Amit Mahipal, M. Roth
Publikováno v:
Annals of Oncology. 30:v279
Background iCCA is a genomically diverse disease where various genomic alterations have been identified. FGFR2 fusions are present in up to 15% of iCCA tumors and are drivers that result in activation of the FGFR pathway. While early studies implicat
Autor:
Amit Mahipal, Steven R. Alberts, Fang-Shu Ou, Sakti Chakrabarti, Jaclynn Wessling, Mitesh J. Borad, Minetta C. Liu, Tyler Zemla, Daniel H. Ahn, Briant Fruth, Robert R. McWilliams, Mindy L. Hartgers, R.L. Walkes
Publikováno v:
Annals of Oncology. 30:v280
Background Advanced BTC is an aggressive neoplasm with median overall survival (OS) of less than a year with current therapy. There is no approved second line therapy. TAS-102, a combination of the thymidine analog trifluridine, and tipiracil an inhi
Autor:
John H. Strickler, Christina Wu, Kimmie Ng, Federico Augusto Sanchez, Patrick McKay Boland, Lorelei Bandel, Joleen M. Hubbard, Nancy E. Kemeny, T. S. Bekaii-Saab, Donna Niedzwiecki, Andrea Cercek, Tyler Zemla, Brandy L. Jaszewski, B. Schweitzer, Fang-Shu Ou
Publikováno v:
Annals of Oncology. 30:v200
Background HER2 (ERBB2) amplification is present in 5-10% of patients (pts) with KRAS and NRAS (RAS) WT mCRC. Tucatinib (Seattle Genetics, Bothell, WA) is a potent, highly selective oral tyrosine kinase inhibitor of the HER2 receptor. In patient-deri
Autor:
Federico Innocenti, Fang-Shu Ou, B. Harms, Donna Niedzwiecki, Charles D. Blanke, Heinz-Josef Lenz, Rahul K Das, C. Washburn, Andrew B. Nixon, Iya Khalil, Alan P. Venook
Publikováno v:
Annals of Oncology. 30:iv116
Autor:
Alan P. Venook, Andrew B. Nixon, D. R. da Cunha, Heinz Joseph Lenz, Boris Hayete, Leon Furchtgott, Jeanne C. Latourelle, Jeffrey A. Meyerhardt, Iya Khalil, Diane Wuest, Federico Innocenti, B. Harms, Rahul K Das, Donna Niedzwiecki, D. Swanson, Charles D. Blanke, Kelly Rich, Eileen M. O'Reilly, Fang-Shu Ou, C. Washburn
Publikováno v:
Annals of Oncology. 29:viii152
Autor:
T. S. Bekaii-Saab, Afsaneh Barzi, Patrick McKay Boland, Jeffrey P. Meyers, Katrina S. Pedersen, Jeff A. Sloan, Nisha L. Jacobs, Fang-Shu Ou, Daniel H. Ahn, Jeannine S. McCune, Kristen K. Ciombor, A. Grothey, Rodwige J. Desnoyers, D.M. Anderson, Mario E. Lacouture, James M. Cleary, Elena G. Chiorean, H. J. Lenz
Publikováno v:
Annals of Oncology. 29:v105